Repeat Variants, Biomarkers, and Molecular Signatures in Parkinson's Disease:

Jose Miguel Laffita-Mesa, Martin Paucar, Per Svenningsson

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Repeat expansions in Parkinson's disease and parkinsonism across ancestries: insights from a global genetic cohort.medRxiv : the preprint server for health sciences · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jose Miguel Laffita-MesaDepartment of Clinical Neuroscience (CNS), Karolinska Institutet, 171 64 Stockholm, Sweden.

Martin PaucarDepartment of Clinical Neuroscience (CNS), Karolinska Institutet, 171 64 Stockholm, Sweden.ORCID 0000-0003-3735-1480

Per SvenningssonDepartment of Clinical Neuroscience (CNS), Karolinska Institutet, 171 64 Stockholm, Sweden.ORCID 0000-0001-6727-3802

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD), the second most common neurodegenerative disorder globally, has a notably high prevalence in Sweden (136/10

Indexed as

Parkinson DiseaseAgedApolipoproteins EAtaxin-2Ataxin-3BiomarkersC9orf72 ProteinCalcium ChannelsCalcium Channels, N-TypeDNA MethylationDNA Polymerase gammaDNA Repeat ExpansionFemaleGenetic Predisposition to DiseaseHumansMaleApoE protein, humanApolipoproteins EAtaxin-2Ataxin-3ATXN2 protein, humanATXN3 protein, humanBiomarkersC9orf72 ProteinC9orf72 protein, humanCACNA1A protein, humanCalcium ChannelsCalcium Channels, N-TypeDNA Polymerase gammaMitochondrial Precursor Protein Import Complex ProteinsPOLG protein, humanPrion ProteinsPRNP protein, humanRepressor Proteinstau ProteinsTOMM40 protein, humanAPOEATXN2C9ORF72genetic risk factorsParkinson’s diseaserepeats expansionsSweden

Identifiers

PMID41009775

DOI10.3390/ijms26189213

PMCPMC12470772

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.